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Abstract: Objective: To detect the expression and clinical significances of Lewis y antigen 
and integrin αv, β3 in epithelial ovarian tumors, and to explore the expression correlation 
between Lewis y antigen and integrin αv, β3. Methods: Immunohistochemical staining was 
performed in 95 cases of epithelial ovarian cancer, 37 cases of borderline tumors, 20 cases 
of benign tumors, and 20 cases of normal ovarian tissue, for the detection of Lewis  y 
antigen and integrin αv, β3 expressions, and to analyze the relationship between Lewis y 
antigen and integrin, and the relationship between clinical and pathological parameters of 
ovarian cancer. In addition, immunofluorescence double labeling was utilized to detect the 
expression correlation  between  Lewis  y  antigen and integrin  αv, β3  in  ovarian cancer. 
Results: In epithelial ovarian tumors, the expression rate of Lewis y antigen was 81.05%, 
significantly  higher  than  that  of  borderline  (51.53%)  (P  <  0.05)  and  benign  (25%)  
(P  <  0.01)  tumors,  and  normal  ovarian  tissues  (0)  (P  <  0.01).  The  expression  rate  of 
integrin  αv,  β3  in  malignant  epithelial  ovarian  tumors  was  78.95%  and  82.11%, 
respectively,  significantly  higher  than  that  of  the  borderline  (45.94%,  40.54%)  (both  
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P < 0.05), benign group (10.00%, 15.00%) (both P < 0.01) and normal ovary group (5%, 
15%) (both P < 0.01). Conclusions: Lewis y and integrins αv, β3 are relevant to pelvic and 
abdominal  diffusion  and  metastasis  of  ovarian  cancer  cells,  suggesting  that  these  two 
molecules mediate a boosting function for tumor metastasis.  
Keywords: epithelial ovarian tumor; integrin αvβ3; Lewis y antigen; immunohistochemistry; 
immunofluorescence double labeling method 
 
1. Introduction 
Ovarian cancer is one of the most common malignancies among women, with an incidence that is 
on the rise, making it a serious danger to female health. In recent years, rapid progress has been made 
in  glycobiology,  particularly  in  the  area  of  glycoconjugates  (glycoproteins,  glycolipids  and 
proteoglycans) on the cell surface, which have been shown to be associated with many physiological 
functions  and  pathological  mechanisms  in  vivo,  such  as  growth  and  development,  organization 
differentiation, protein intracellular transport, immune response, inflammation, carcinogenesis, etc. [1]. 
The relationships between glycoconjugates and tumors have received the most attention. Researchers 
have demonstrated that the malignant behaviors of tumor cells, such as invasion and metastasis, are all 
closely related to structure changes of sugar chains, which are the main component of glycoconjugates 
on the cell surface. Significant changes in the structure of the sugar chain on the membrane surface 
have been observed in the malignant process, affecting the structure and function of glycolipids and 
glycoproteins, both of which carry sugar chains [2]. 
Lewis y belongs to the Lewis blood group antigen family, which is a member of the blood group 
related  antigens  including  A,  B,  H  and  Lewis  antigen  family.  Lewis  y  antigen  is  located  on  the 
molecular ends of glycoproteins and glycolipids on the cell surface and belongs to oligosaccharides of 
two-fucose  glycosylation.  Lewis  y  antigen  is  expressed  in  early  development  of  embryos,  and  its 
expression is limited to white blood cells and some epithelial cells in adults [3]. Lewis y antigen is 
expressed in some normal epithelial tissues and their secretions, however, overexpression is observed 
on the cell surface of most glandular epithelial origin tumors, including breast, ovarian, pancreatic, 
prostate, colorectal and non-small cell lung cancers [4]. Lewis y antigen expression is closely related to 
malignant processes and tumor cell proliferation, differentiation, invasion and metastasis behaviors.  
As  an  important  component  of  adhesion  molecules,  integrin  molecules  mediate  cell–cell  and  
cell–extracellular  matrix  (ECM)  interactions,  which  play  many  important  roles  in  tumor  growth, 
invasion,  metastasis, and drug resistance  [5]. Our previous study  confirmed that the structure and 
expression of Lewis y antigen are significantly correlated with integrin α5β1, and that Lewis y antigen 
plays an important role in ovarian cancer adhesion and resistance mediated by integrin α5β1 [6]. Our 
results  show  a  close  relationship  between  the  Lewis  y  antigen  and  the  integrin  family.  Another 
important member of the integrin family, integrin αvβ3, is highly expressed on the surface of many 
cancer cells [7]. 
In this study, we used immunohistochemistry to explore the expression pattern of Lewis  y and 
integrins αvβ3, as well as their correlation in ovarian malignant epithelial tumors, borderline tumors, Int. J. Mol. Sci. 2011, 12                       
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benign  and  normal  ovarian  tissues,  and  to  analyze  their  relationship  with  clinicopathological 
parameters of ovarian cancer. Immunofluorescence double labeling was performed to further confirm 
the correlation between the Lewis y and integrin αv, β3. Our study provides a theoretical mechanism 
and a possible target for the development of future of biological treatment for ovarian cancer. 
2. Results 
2.1. Expression of Lewis y Antigen, Integrin αv and β3 in Different Ovarian Tissues 
Lewis y antigen was expressed in the cytoplasm and cell membrane, with the majority of Lewis y 
on membrane, with a lack of staining in the nucleus. Lewis y antigen positive expression rate was 
81.05% in the epithelial ovarian tumor group, significantly higher than that of the borderline group 
(51.35%) (P < 0.05) and the benign group (25.00%) (P < 0.01). Lewis y antigen positive rate was 
higher in the borderline group than in the benign group, with no statistically significant difference  
(P > 0.05). No Lewis y antigen expression was detected in the 20 normal ovary tissues, as shown  
in Table 1. 
Table 1. Expression of Lewis y antigen in different ovarian tissues. 
Groups 
Lewis y Antigen 
N (cases)  −  + ~ +++  Positive Rate (%) 
malignant group  95  18  77  81.05 * 
borderline group  37  18  19  51.35 ** 
benign group  20  15  5  25.00 
normal group  20  20  0  0 
Note: * malignant group is compared with other groups; ** borderline group is compared with benign group. 
The expression of integrin αv and β3 were mainly on membrane, which is similar to Lewis y. The 
integrin αv positive expression rate was 78.95% in the ovarian malignant group, significantly higher 
than that of the borderline group (45.94%), the benign group (10.00%), and normal ovarian tissue 
(5.00%) (all P < 0.01). The positive expression rate of the borderline group was significantly higher 
than that of the benign group and normal ovarian tissues (all P < 0.01). There was no significant 
difference between benign and normal ovarian tissues (P > 0.05).  
The positive expression rate of integrin β3 in the ovarian cancer group (82.11%) was significantly 
higher than that of the borderline group (40.54%) (P < 0.05), the benign group (15.00%) (P < 0.01) 
and normal ovarian tissues (15.00%) (P < 0.01). The positive expression rate of the ovarian borderline 
group was significantly higher than that of the benign group and normal ovarian tissues (all P < 0.05). 
There was no significant difference in β3 positive expression rate between benign and normal ovarian 
tissue (Table 2, Figure 1).  Int. J. Mol. Sci. 2011, 12                       
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Table 2. Expression of integrin αv, β3 in different ovarian tissues. 
Groups  Cases 
Integrin αv  Positive 
Cases 
Positive 
Rate (%) 
Integrin β3  Positive 
Cases 
Positive 
Rate (%)  −  +  ++  +++  −  +  ++  +++ 
malignant group  95  20  17  21  37  75  78.95 *  17  18  35  25  78  82.11 * 
borderline group  37  20  7  7  3  17  45.94 *  22  6  5  4  15  40.54 * 
benign group  20  18  2  0  0  2  10.0  17  2  1  0  3  15.00 
normal group  20  19  1  0  0  1  5.00  17  2  1  0  3  15.00 
Note: * malignant group, borderline group are compared with benign group and normal group, respectively. 
Figure 1. Immunohistochemical staining in ovarian malignant tumor (A1–A3), borderline 
tumor (B1–B3), benign tumor (C1–C3) and normal ovarian tissue (D1–D3). Integrin αv 
(A1,  B1,  C1,  D1);  β3  (A2,  B2,  C2,  D2)  and  Lewis  y  (A3,  B3,  C3,  D3).  (Original 
magnification × 200). 
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2.2. Expression of Lewis y Antigen and Integrin αv, β3 and Their Relationships with Clinical and 
Pathological Parameters of Ovarian Cancer 
In 95 patients with ovarian cancer, the Lewis y antigen positive rate in the abdominal metastasis 
group  (91.67%)  was  higher  than  that  in  the  group  without  abdominal  metastasis  (62.85%),  with 
statistically significant difference (P < 0.01). The Lewis  y positive expression rate of the ovarian 
cancer  with  high-moderate  differentiated  and  poorly  differentiated  groups  were  58.82%,  88.89%, 
respectively, with a statistically significant difference (P < 0.05). The Lewis y expression rate was 
significantly higher in the CA125-positive group (86.67%) than in the CA125 negative group (60.00%) 
(P < 0.05). Lewis y positive expression rate was higher in ovarian cancer Ⅲ-IV stage (90.00%) than in 
the  I-II  stage  (78.67%),  but  the  difference  between  two  groups  was  not  statistically  significant  
(P > 0.05) (Table 3). 
Table  3.  Relationship  between  Lewis  y  antigen  with  the  clinical  and  pathological 
parameters of malignant ovarian cancer. 
Characteristics  n 
Lewis y 
P  X
2 
−  + ~ +++  Positive Rate (%) 
FIGO Stages 
I~II  75  18  59  78.67 
>0.05  1.736 
III~IV  20  2  18  90.00 
Histological Grades 
high-moderate  68  28  40  58.82 
<0.05  9.196 
poorly  27  3  24  88.89 
Abdominal Diffusion Metastasis 
No  35  13  22  62.85 
<0.01  11.947 
Yes  60  5  55  91.67 
CA125 
negative  20  8  12  60.00 
<0.05  7.311 
positive  75  10  65  86.67 
Integrin αv expression rates in the abdominal metastasis group (96.67%) was significantly higher 
than that in the group without abdominal metastasis (48.57%) (P < 0.01). The integrin αv positive 
expression rate  was  73.53% and 92.59% in  high-moderate differentiated and poorly  differentiated 
groups, respectively, with the statistically significant difference (P < 0.05). The expression rate in the 
CA125-positive group (80.00%) was slightly higher than in the CA125-negative group (75.00%), with 
no significant difference (P > 0.05). The integrin αv expression rate in ovarian cancer III~IV stage 
(75.00%) was slightly lower than in the I~II stage (80.00%), with no significant difference (P > 0.05) 
(Table 4). Int. J. Mol. Sci. 2011, 12                       
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Table 4. Relationship between integrin αv with the clinical and pathological parameters of 
malignant ovarian cancer.  
Characteristics  n 
Lewis y 
P  X
2 
−  + ~ +++  Positive Rate (%) 
FIGO Stages 
I~II  75  15  60  80.00 
>0.05  0.238 
III~IV  20  5  15  75.00 
Histological Grades 
high-moderate  68  18  50  73.53 
<0.05  4.226 
poorly  27  2  25  92.59 
Abdominal Diffusion Metastasis 
No  35  18  17  48.57 
<0.05  30.765 
Yes  60  2  58  96.67 
CA125 
negative  20  5  15  75.00 
>0.05  0.238 
positive  75  15  60  80.00 
Expression  of  integrin  β3  was  significantly  different  only  in  the  abdominal  diffusion  transfer  
(P < 0.01), and showed no correlation with clinical staging, CA125 expression or histological grade  
(P > 0.05) (Table 5).  
Table 5. Relationship between integrin β3 with the clinical and pathological parameters of 
malignant ovarian cancer. 
Characteristics  n 
Lewis y 
P  X
2 
−  + ~ +++  Positive Rate (%) 
FIGO Stages 
I~II  75  13  62  82.67 
>0.05  0.076 
III~IV  20  4  16  80.00 
Histological Grades 
high-moderate  68  15  53  77.94 
>0.05  2.824 
poorly  27  2  25  92.59 
Abdominal Diffusion Metastasis 
No  35  15  20  51.74 
<0.01  23.503 
Yes  60  2  58  96.67 
CA125 
negative  20  5  15  75.00 
>0.05  0.870 
positive  75  12  63  84.00 
Thus, abdominal metastasis has the highest degree of consistency among the clinical pathology 
parameters which were correlated with Lewis y, integrin αv and β3 expression in ovarian cancer. 
2.3. Correlation Analysis between Expression of Lewis y Antigen and Integrin αv, β3 in Ovarian Cancer 
A similar trend was seen in the expression of Lewis y antigen, integrin αv, β3 in 95 patients with 
ovarian  cancer,  according  to  the  results  of  immunohistochemistry.  In  order  to  investigate  the Int. J. Mol. Sci. 2011, 12                       
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correlation between these two antigens, we performed Spearman correlation analysis for each set of 
data, which demonstrated a high degree of positive correlation between Lewis y and integrin αv, β3 
subunits (all P < 0.001) (correlation coefficients were 0.731, 0.605, respectively) (Tables 6 and 7). The 
Kappa test revealed consistency between Lewis y antigen and integrin αv or β3 subunit expression  
(P = 0.000), while Lewis y showed a slightly higher correlation with integrin αv subunit than with  
β3 subunit. 
Table 6. Correlation between expression of Lewis y antigen and integrin αv in ovarian cancer. 
Lewis y (n) 
Integrin αv (n) 
R  P 
− (20)  + (17)  ++ (21)  +++ (37) 
− (18) 
+ (15) 
++ (20) 
+++ (42) 
12 
5 
2 
1 
3 
8 
4 
2 
2 
1 
10 
8 
1 
1 
4 
31 
0.731  0.000 
Table 7. Correlation between expression of Lewis y antigen and integrin β3 in ovarian cancer. 
Lewis y (n) 
Integrin β3 (n) 
R  P 
− (17)  + (21)  ++ (18)  +++ (39) 
− (18) 
+ (15) 
++ (20) 
+++ (42) 
10 
4 
2 
1 
3 
8 
4 
6 
2 
1 
11 
4 
3 
2 
3 
31 
0.605  0.000 
In addition, immunofluorescence double-labeling revealed that in ovarian cancer Lewis y antigen 
(red  fluorescence)  was  localized  in  the  cell  membrane  and  cytoplasm.  Integrin  αv  and  β3  (green 
fluorescence) were mainly localized in the cell membrane, with a small amount of coloring in the 
cytoplasm. The 4,6-diamino-2-phenyl indole (DAPI) (blue fluorescence) was used to visualize the 
nucleus. In three-channel synthesized images, the yellow fluorescence emerges from the area emitting 
both  red  and  green  fluorescence,  indicating  co-localization  of  Lewis  y  antigen  and  integrin  αv,  
β3 (Figure 2). 
Figure 2. Integrin αv, β3 and Lewis y colocalize in ovarian malignant tumor. Using an 
immunofluorescent double-labeling method. Integrin αv and β3 (A1 and B1); Lewis y (A2 
and B2); nucleus (A3 and B3); Merged image (A4 and B4). (Original magnification × 400). 
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Figure 2. Cont. 
 
B1       B2              B3      B4 
3. Discussion 
Glycoproteins, glycolipids and proteoglycans with differing compositions and structures exist on 
the cell surface, the sugar chains of which form antenna-like branches to receive information. These 
sugar chains play a key role as receptors for signaling molecules and are closely related to adhesion 
and  recognition  between  cells,  cell  malignant  transformation,  invasion  and  metastasis.  Lewis  y  is 
present in epithelial tissues, and during carcinogenisis, Lewis y expression was significantly increased 
in  60%  to  90%  patients  with  a  poor  prognosis  [8],  thus  indicating  it  may  serve  as  a  marker  for  
disease severity.  
Yin et al. [9] found a positive expression rate and a strong positive expression rate of Lewis y 
antigen in ovarian carcinoma was 75% and 56%, respectively. Among 11 types of ovarian cancer cell 
lines  tested,  7  cell  lines  were  found  to  be  Lewis  y  antigen  positive.  Baldus  et  al.  [10]  used 
immunohistochemistry  to  detect  Lewis  y  antigen  in  44  cases  of  colorectal  adenocarcinoma  and  
42 cases of colorectal adenomas and found that the Lewis y antigen expression level was enhanced 
with adenoma degeneration and higher histological grade, suggesting that Lewis y antigen expression 
is related to the cell's degree of malignancy. Our previous work [11] also demonstrated that enhanced 
expression  of  Lewis  y  antigen  increases  the  proliferation,  adhesion,  invasion,  metastasis,  drug 
resistance and other capacities of ovarian cancer cells. This study found the Lewis  y antigen was 
highly expressed in epithelial ovarian cancer, with the positive rate of 81.05%, significantly higher 
than that of the borderline (51.35%) (P < 0.05), or the benign (25.00%) (P < 0.01), tumor group. In 
epithelial ovarian cancer, the Lewis y antigen positive rate in poorly differentiated group was 88.89%, 
significantly higher than in the high-moderate differentiated group (58.82%) (P < 0.05). It can be seen 
that  the  expression  of  the  Lewis  y  antigen  is  increased  with  the  increase  of  malignant  degree, 
indicating a positive correlation between Lewis y antigen and ovarian cancer malignancy. Our results 
also showed that Lewis y expression is significantly related to the abdominal metastasis of epithelial 
ovarian cancer (P < 0.01). Taken together, these results indicate a correlation between the expression 
of Lewis y antigen and the occurrence and development of ovarian cancer.  
The integrin family belongs to the cell adhesion molecules membrane receptor family, and can 
promote the growth, metastasis, angiogenesis and drug resistance of ovarian cancer. Due to its role  
in  tumor  cell  adhesion,  integrin  overexpression  may  promote  tumor  cell  invasion,  adhesion  and 
metastasis [12]. Integrin is also a mediator of angiogenesis, thereby promoting tumor growth, local 
invasion and distant metastasis. For instance, integrin αv, β3 is closely related to tumor invasion, 
metastasis  and  angiogenesis  in  ovarian  cancer,  malignant  melanoma,  breast  cancer  and  prostate  Int. J. Mol. Sci. 2011, 12                       
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cancer [13]. Numerous studies have confirmed that integrin αv plays an important role in ovarian 
cancer progression and metastasis [14–17]. By activating integrin-linked kinase (IL-K), the integrin αv 
subunit promotes growth and proliferation of ovarian cancer cells, and mediates their adhesion and 
migration [18]. Integrin αv also promotes the adhesion of human ovarian epithelial cells (HOSE) to 
VN, is actively involved in cell proliferation and necessary for HOSE maximum proliferation [19]. 
Integrin αv, β3 overexpression significantly enhanced adhesion and proliferation of VN-dependent 
human ovarian cancer cell line OV-MZ-6, and enhanced the cell motility 5 folds in the adhesion of 
OV-MZ-6  cells  to  VN,  accompanied  by  significant  changes  in  cytoskeletal  structure  and  cell 
morphology [20]. In this study, integrin αv, β3 expression was correlated to peritoneal metastasis, 
consistent with the Lewis y antigen results, suggesting that αv and β3 may both be involved in the 
mechanisms underlying peritoneal metastasis of ovarian cancer.  
Researchers have shown that the mechanisms underlying changes in ovarian cancer physiological 
changes by Lewis y antigen are related to cell surface receptor proteins. Lewis y is connected to many 
end  oligosaccharide  chains  of  cell  surface  receptors,  regulating  cell  biological  behaviors  through 
modification of cell surface receptors. In Lewis y antigen high expression tumor cells, Bsau et al. [21] 
have  observed  the  presence  of  Lewis  y  antigen  in  epidermal  growth  factor  receptor  (EGFR).  
Klinger  et  al.  [22]  found  that  blocking  Lewis  y  antigen  with  specific  antibodies  could  affect  the 
corresponding  cell  surface  EGFR  family-mediated  cell  signal  transduction,  changes  in  subcellular 
localization  of  signal  substances,  and  accelerated  cell  surface  recycling.  Epithelial  ovarian  cancer 
tumor marker CA125 has also been shown to contain the Lewis y antigen structure [23]. In addition, 
the Lewis y expression rate in CA125-positive ovarian cancer was 86.67%, significantly higher than 
that in CA125-negative ovarian cancer (60.00%), with statistically significant difference (P < 0.05). 
The data from the current study indicate that Lewis y and CA125 are highly relevant, in agreement 
with  the  previous  published  results.  Integrins  are  receptor  proteins  on  the  cell  surface,  with  the 
extracellular  matrix  serving  as  their  ligands.  Our  previous  work  demonstrated  that  the  Lewis  y 
structure existed in integrin α5β1 [6]. The results of this paper show that in epithelial ovarian cancer, 
Lewis y and integrin αv, β3 expression is highly relevant and consistent. Analysis showed a significant 
positive correlation between Lewis  y antigen and integrin αv and β3 expression in ovarian cancer  
(R  =  0.731,  P  =  0.000;  R  =  0.605,  P  =  0.000).  Immunofluorescence  double  labeling  indicates  
co-localization of Lewis y antigen and integrin αv, β3 in ovarian cancer tissues, further proving their 
close relationship.  
Therefore,  we  can  speculate  that  Lewis  y  antigens  may  be  an  important  sugar  chain  structure 
associated with integrin αv, β3, and it can be exposed directly to the extracellular matrix, detecting 
extracellular  microenvironment  changes,  thereby  affecting  integrin  αv,  β3  function  and  regulating 
ovarian cancer cell biological behaviors, including adhesion and migration. 
4. Materials and Methods 
4.1. Case Information and Tissue Samples 
All clinical surgical tissues were collected from 2003 to 2009 in the Second Affiliated Hospital of 
Dalian  Medical  University  and  Dalian  Maternity  Hospital.  All  tissue  slices  were  re-confirmed  by Int. J. Mol. Sci. 2011, 12                       
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pathology experts. There were 95 cases of primary epithelial ovarian cancer, 37 cases of borderline 
ovarian epithelial tumors, 20 cases of benign ovarian epithelial tumors, and 20 cases of normal ovarian 
tissue  (from  normal  ovarian  specimens  cut  in  the  same  period  of  cervical  cancer  surgery),  from 
patients  ranging  in  age  from  27  to  68  years  (average  42.8  years).  The  clinical  and  pathological 
parameters of ovarian cancer patients include abdominal metastasis, clinical stage, histological grade, 
routine immunohistochemistry results of CA125. According to histological grade, among the 95 cases 
of  ovarian  cancer  studied,  there  were  20  cases  of  high  differentiated,  48  cases  of  moderate 
differentiated,  and  27  cases  of  poorly  differentiated.  Clinical  stage  [according  to  International 
Federation  of  Gynecology  and  Obstetrics  (FIGO)  criteria]:  75  cases  of  I~II  stage,  20  cases  of  
III~IV stage. Among these 95 cases of ovarian cancer, 60 cases showed spread and metastasis in pelvic 
and  abdominal  cavities  (including  20  cases  uterine  surface  metastasis,  20  cases  of  tubal  surface 
metastasis, and 20 cases of peritoneal surface metastasis). Seventy-five (75) cases were positive for 
CA125 expression. 
4.2. Main Reagents 
Rabbit  anti-human  integrin  αv,  β3  polyclonal  antibody  was  purchased  from  Wuhan  Boster 
Company,  mouse  anti-human  Lewis  y  monoclonal  antibody  was  purchased  from  Abcam  Inc., 
biotinylated goat anti-mouse IgM, biotinylated goat anti-mouse IgG were purchased from Zhongshan 
Biotechnology  Co.,  Ltd.  Serum  albumin  (BSA)  and  DAB  kit  were  purchased  from  Zhongshan 
Biotechnology Co., Ltd. Goat anti-rabbit IgG fluorescein isothiocyanate (FITC) and goat anti-mouse 
IgG tetraethyl rhodamine isothiocyanate (TRITC) were purchased from Fujian Wanxin company, and 
DAPI was purchased from Shenyang Baoxin company. 
4.3. Immunohistochemistry 
Streptavidin-biotin-peroxidase (SP) immunohistochemistry was performed. Tissues were fixed in 
4% formaldehyde and embedded in paraffin, and 4 mm thick serial sections were prepared at the same 
organizational part. The working concentrations of Lewis y antibody and integrin αv, β3 antibody were 
1:200 and 1:100, respectively. The staining procedure was performed according to SP kit manual. The 
group with PBS instead of primary antibody was used as a negative control. A colon cancer sample 
served as positive control for Lewis y antigen, and a breast cancer sample was a positive control for 
integrin αv, β3. 
4.4. Immunofluorescence 
The  sample  slices  of  strong  expression  for  immunohistochemistry  were  selected  to  performed 
immunofluorescence double labeling method. Primary antibody combinations were anti-integrin αv 
with anti-Lewis y, or anti-integrin β3 with anti-Lewis y, with the PBS instead of primary antibody as 
the negative control.  The working concentrations  of rabbit anti-human integrin αv, β3  and mouse  
anti-human Lewis y antibody were all 1:100. The working concentrations of goat anti-rabbit IgM FITC 
and goat anti-mouse IgG TRITC were 1:100. The working concentration of nuclear dye DAPI was 
1:100. The staining was performed according to the instructions of immunofluorescence kit. Int. J. Mol. Sci. 2011, 12                       
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4.5. The Determination of Results 
The presence of brown colored granules on the cell membrane or in the cytoplasm was taken as a 
positive signal, and was divided by color intensity into not colored, light yellow, brown, tan and is 
recorded as 0, 1, 2, and 3, respectively. We choose five high-power fields in series from each slice, 
then score them and take the average percentage of chromatosis cells. A positive cell rate of less than 
5% was a score of 0, a positive cell rate of 5~25% was a score of 1, a positive cell rate of 26~50% was 
a score of 2, positive cell rate of 51~75% was a score of 3, positive cell rate of more than 75% was a 
score of 4. The final score was determined by multiplying positive cell rate and score values: 0~2 was 
equal to negative expression (−), 3~4 was equal to weakly positive (+), 5~8 was equal to moderate 
positive (++), 9~12 was equal to strong positive (+++). The results were read by two independent 
observers to control for variability.  
Microscopic  red  fluorescence indicated  Lewis  y  antigen labeled by  TRITC,  green fluorescence 
indicated integrin αv, β3 labeled by FITC, while blue fluorescence indicated DAPI-stained nucleus. 
Pictures  of  the  three  individual  fluorescence  channels  were  superimposed  using  image  analysis 
software, with a yellow fluorescence indicated co-localization of Lewis y antigen and integrin αv, β3.  
4.6. Statistical Analysis 
Statistical  analyses  were  performed  using  the  SPSS  software  Version  11.5.  Data  expressed  as  
mean ±  SD was applied for statistical  analysis. The Student’s t test  was applied to  compare data 
between the two groups, and analysis of variance was applied to compare data among multiple groups. 
The Chi-square (χ
2) test was applied to analyze the expression of Lewis y antigen, integrin αv, β3  
and  clinicopathological  parameters.  The  Spearman  correlation  analysis  method  was  applied  to 
calculate the coefficient R of indexes and to analyze its correlation, A P value <0.05 was considered 
statistically significant.  
5. Conclusions 
In summary,  Lewis  y  and integrins  αv, β3  are relevant  to  pelvic and  abdominal  diffusion  and 
metastasis of ovarian cancer cells, suggesting that these two molecules mediate a boosting function for 
tumor metastasis. 
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